Anvisa, the health regulator of Brazil, has extended the validity of the single-shot US pharmaceutical company Johnson & Johnson (J&J) (NYSE:JNJ) COVID-19 vaccine, prolonging its shelf life from three months to 4.5 months, Reuters news agency reported on Tuesday.
This gives Brazil more time to use a first batch due to arrive this week.
Reportedly, the batch of three million doses was due to expire on 27 June 2021, but now Brazil has followed the US Food and Drug Administration in extending the expiration dates by a month a half.
Brazil's Health Minister said the vaccines should arrive on Wednesday, a day later than stated last week.
Reportedly, Brazil had signed an agreement with the J&J-owned Belgian laboratory Janssen to receive 38 million doses for delivery in the last quarter of this year.
This first batch of vaccine doses is arriving earlier than originally planned.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial